These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20415778)

  • 1. Modified vaccination technique for prophylactic and therapeutic applications to combat endogenous antigen-induced disorders.
    Barabas AZ; Cole CD; Barabas AD; Graeff RM; Lafreniere R; Weir DM
    Scand J Immunol; 2010 Mar; 71(3):125-33. PubMed ID: 20415778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Ann N Y Acad Sci; 2007 Sep; 1110():619-29. PubMed ID: 17911477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique.
    Barabas AZ; Cole CD; Barabas AD; Graeff RM; Lafreniere R; Weir DM
    Autoimmun Rev; 2009 Jun; 8(7):552-7. PubMed ID: 19393215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathological events initiated and maintained by pathogenic IgG autoantibodies in an experimental autoimmune kidney disease.
    Barabas AZ; Cole CD; Lafreniere R; Weir DM
    Autoimmunity; 2012 Nov; 45(7):495-509. PubMed ID: 22816962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccination technology for endogenous antigen-derived ailments.
    Barabas AZ; Cole CD; Barabas AD; Bahlis NJ; Lafreniere R
    IDrugs; 2008 Feb; 11(2):111-5. PubMed ID: 18240096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated antibody response by antigen presentation in immune complexes.
    Barabas AZ; Cole CD; Kovacs ZB; Lafreniere R
    Med Sci Monit; 2007 May; 13(5):BR119-24. PubMed ID: 17476190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-initiated beneficial and harmful immune responses.
    Barabas AZ; Cole CD; Lafreniere R
    Immunol Res; 2018 Dec; 66(6):783-789. PubMed ID: 30456543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The modified vaccination technique designed to prevent and cure acute and chronic disorders.
    Barabas AZ; Cole CD; Kovacs ZB; Kovacs EI; Lafreniere R; Weir DM
    Hum Antibodies; 2020; 28(2):111-121. PubMed ID: 31594214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic cancer vaccines.
    Acres B; Paul S; Haegel-Kronenberger H; Calmels B; Squiban P
    Curr Opin Mol Ther; 2004 Feb; 6(1):40-7. PubMed ID: 15011780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerance, loss of tolerance and regaining tolerance to self by immune-mediated events.
    Barabas AZ; Cole CD; Graeff RM; Lafreniere R; Weir DM
    Immunol Res; 2017 Feb; 65(1):402-409. PubMed ID: 27456203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease.
    Barabas AZ; Lafreniere R
    Autoimmun Rev; 2005 Nov; 4(8):565-70. PubMed ID: 16214097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane.
    Satoh M; Hamilton KJ; Ajmani AK; Dong X; Wang J; Kanwar YS; Reeves WH
    J Immunol; 1996 Oct; 157(7):3200-6. PubMed ID: 8816434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor vaccination: where we stand.
    Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel modified vaccination technique produces IgG antibodies that cause complement-mediated lysis of multiple myeloma cells carrying CD38 antigen.
    Barabas AZ; Cole CD; Graeff RM; Morcol T; Lafreniere R
    Hum Antibodies; 2016; 24(3-4):45-51. PubMed ID: 28128764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network.
    Weathington NM; Blalock JE
    Expert Rev Vaccines; 2003 Feb; 2(1):61-73. PubMed ID: 12901598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of autoimmunologists in investigating and treating autoimmune disorders.
    Barabas AZ; Cole CD; Graeff RM; Lafreniere R; Weir DM
    Autoimmun Rev; 2011 Jan; 10(3):166-70. PubMed ID: 20887816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer vaccines: challenges and outlook in the field.
    Paul S; Acres B; Limacher JM; Bonnefoy JY
    IDrugs; 2007 May; 10(5):324-8. PubMed ID: 17487784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis.
    Barabas AZ; Cole CD; Barabas AD; Lafreniere R
    Pathol Int; 2006 Apr; 56(4):181-90. PubMed ID: 16634963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity.
    Steinman L
    J Intern Med; 2010 May; 267(5):441-51. PubMed ID: 20433574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.